期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

重组人红细胞生成素治疗恶性肿瘤贫血最佳剂量的探讨 被引量：1

原文传递
导出
摘要 目的对重组人红细胞生成素(rhEPO)治疗恶性肿瘤贫血的最佳剂量进行初步探讨。方法将符合条件的131例恶性肿瘤贫血患者随机分为rhEPO 50 U/kg组、rhEPO 100 U/kg组、rhEPO 150 U/kg组、rhEPO 200 U/kg组、rhEPO 400 U/kg组和安慰剂组,共观察8周,每2周进行1次疗效比较。结果①rhEPO 50U/kg组的有效率低于其他各rhEPO组(P<0.05或0.01)。②rhEPO 100 U/kg组与高于其剂量的各rhEPO组在显效时间、升高血红蛋白值、提高患者生活质量、降低输血需求率、药物不良反应发生率以及有效率方面差异均无统计学意义(均P>0.05)。结论①rhEPO 50 U/kg组治疗恶性肿瘤贫血的疗效低于其他各rhEPO组(100～400 U/kg),而在rhEPO 100～400 U/kg的剂量范围内,其疗效未发现随剂量的增加而明显增高,因此建议将rhEPO 100 U/kg作为适合国人的最佳剂量试用于临床。②rhEPO治疗恶性肿瘤贫血的疗效可能存在着种族之间的差异。
作者 孙衍伟 安永恒 丁兆军 周嘉云 梁军
机构地区 山东省日照市人民医院肿瘤科 青岛大学附属医院肿瘤科
出处 《中国综合临床》 北大核心 2007年第9期791-793,共3页 Clinical Medicine of China
关键词 恶性肿瘤 重组人红细胞生成素 贫血
分类号 R730.53 [医药卫生—肿瘤]
  • 相关文献

参考文献7

  • 1Rizzo JD, Lichtin AE, Woolf SH, et al. Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American society of clinical oncology and the american society of hematology[ J ]. Blood ,2002,100 (7) :2303-2320.
  • 2Mantovani G, Ghiani M, Gurreki L, et al. Assessment of the efficancy of two dosages and schedules of human recombinant erythropoietin in the prevention and COlTection and con'ection of cisplation induced anemia in cancer patients[J]. Oncol Rep,1999,6(2) :421-426.
  • 3Olsson AM, Svensson JH, Sundstrom J, et al. Erythropoietin treatment in metastatic breast cancer-effects on Hb,quality of life and need for transfusion[J]. Acta Oncol,2002,41 (6) :517-524.
  • 4肖志华,汤昊,柯玉华,蒋晖,于丁.重组人红细胞生成素治疗肿瘤化疗所致贫血的临床观察[J].临床肿瘤学杂志,2005,10(2):193-194. 被引量：6
  • 5Santin A.D.,Bellone S.,Siegel E.R.,朱国栋.Ⅱ型表皮生长因子受体(HER2/neu)过度表达的种族差异:子宫浆液性乳头状癌的主要预后指标[J].世界核心医学期刊文摘（妇产科学分册）,2005,0(7):13-14. 被引量：2
  • 6Jones-Burton C, Seliger SL. Racial variations in erythropoietic response to epoetin alfa in chronic kidney disease and the impact of smoking[J]. Nephrol Dial Transplant,2005,20(12) :2739-2745.
  • 7杨婉华,王常玉,王世宣,卢运萍,朱涛,马丁.重组人红细胞生成素在恶性肿瘤贫血中的应用[J].中国妇产科临床杂志,2002,3(2):81-84. 被引量：4

二级参考文献14

  • 1[1]David H. Supplemental Iron: A Key to Optimizing the Response of Cancer- Related Anemia to rHuEPO? The Oncologist , 1998, 3:275-278
  • 2[2]徐有恒,王倚如,主编.造血生理学和造血细胞检测技术.第1版.湖南:湖南科学技术出版社,1996.298-345
  • 3[4]Coiffier B. The impact and management of anaemia in haematological malignancies. Med Oncol, 2000, 17 (Suppl 1): 2- 10
  • 4[5]Spivak JL. C ancer- related anemia: its causes and characteristics. Semin Oncol, 1994, 21 (2 Suppl 3): 3 - 8
  • 5[6]Faquin WC, Schneider TJ, Goldberg MA. Effect of inflammatory cytokines on hypoxia- induced erythropoietin production. Blood, 1992, 15:1987 - 1994
  • 6[7]Jason TE, Lisa S, Robert K, et al. A retrospective review of blood transfusion in cancer patients. The Oncologist, 1999, 4:318 - 324
  • 7[8]Miller CB, Jones RJ, Piantadosi S, et al. Decreased erythropoietin response in patients with the anemia of cancer. N Engl J Med, 1990, 14:1689- 1692
  • 8[9]Del mastroaL, MarcoV. Strategies for the Use of Epoetin Alfa in Breast Cancer Patients. The Oncologist, 1998 , 3: 314- 318
  • 9[10]Cazzola M. How and when to use erythropoietin? Curr Opin Hematol,1998, 5: 103- 112
  • 10[11]Lim VS, DeGowin RL, Zavala D, et al. Recombinant human erythropoietin treatment in pre - dialysis patients: Double - blind placebocontrolled trials. Ann Intern Med, 1989 , 15:108 - 114

共引文献9

同被引文献9

  • 1陈衍,刘文超,程婕.癌性贫血的最新临床研究进展[J].现代肿瘤医学,2008,16(11):1995-1998. 被引量：13
  • 2徐菲,张力,向晓娟,王志强,周中梅,王思阳.重组人红细胞生成素大剂量冲击维持疗法治疗30例肿瘤相关贫血的临床报告[J].癌症,2006,25(9):1120-1122. 被引量：7
  • 3Rizzo JD,Lichtin AE,Woolf SH. Use of epoetin in patients with cancer:evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology[J].Journal of Clinical Oncology,2002,(19):4083-4107.
  • 4Chung I J,Dai C,Krantz SB. Stem cell factor increases the expression of FLIP that inhibits IFNgamma-induced apoptosis in human erythroid progenitor cells[J].Blood,2003,(04):1324-1328.
  • 5Waltzman RJ,Williams D,Braly P. A pilot study to evaluate the safety and clinical outcomes of once-weekly epoetin alfa 80,000 u in anemic patients with cancer receiving chemotherapy[J].Support Cancer Ther,2005,(01):47-53.
  • 6Cortesi E,Mancuso A,De Pasquale Ceratti A. Effectiveness and safety of an induction therapy with epoetin alfa in anemic cancer patients receiving concomitant chemotherapy[J].Oncologist(The),2004,(04):459-468.
  • 7Fujisaka Y,Sugiyama T,Saito H. Randomised,phase Ⅲ trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation[J].British Journal of Cancer,2011,(09):1267-1272.
  • 8Rizzo JD,Brouwers M,Hurley P. American society of clinical 0ncology/american society of hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer[J].J Oncol Pract,2010,(06):317-320.
  • 9费立升.大剂量宁红欣冲击治疗恶性肿瘤贫血的疗效观察[J].中华全科医学,2012,10(4):550-550. 被引量：2

引证文献1

中国综合临床
2007年 第9期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部